These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34548332)

  • 1. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
    Haikala HM; Lopez T; Köhler J; Eser PO; Xu M; Zeng Q; Teceno TJ; Ngo K; Zhao Y; Ivanova EV; Bertram AA; Leeper BA; Chambers ES; Adeni AE; Taus LJ; Kuraguchi M; Kirschmeier PT; Yu C; Shiose Y; Kamai Y; Qiu Y; Paweletz CP; Gokhale PC; Jänne PA
    Cancer Res; 2022 Jan; 82(1):130-141. PubMed ID: 34548332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
    Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
    Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
    Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
    Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
    Yu HA; Goto Y; Hayashi H; Felip E; Chih-Hsin Yang J; Reck M; Yoh K; Lee SH; Paz-Ares L; Besse B; Bironzo P; Kim DW; Johnson ML; Wu YL; John T; Kao S; Kozuki T; Massarelli E; Patel J; Smit E; Reckamp KL; Dong Q; Shrestha P; Fan PD; Patel P; Sporchia A; Sternberg DW; Sellami D; Jänne PA
    J Clin Oncol; 2023 Dec; 41(35):5363-5375. PubMed ID: 37689979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting HER3 to overcome EGFR TKI resistance in NSCLC.
    Chen Q; Jia G; Zhang X; Ma W
    Front Immunol; 2023; 14():1332057. PubMed ID: 38239350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced
    Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA
    Future Oncol; 2024 May; 20(15):969-980. PubMed ID: 38095056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
    Koyama K; Ishikawa H; Abe M; Shiose Y; Ueno S; Qiu Y; Nakamaru K; Murakami M
    PLoS One; 2022; 17(5):e0267027. PubMed ID: 35503762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
    Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA
    Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
    Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
    Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
    Liu B; Chen D; Chen S; Saber A; Haisma H
    Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers.
    Chang YF; Lim KH; Chiang YW; Sie ZL; Chang J; Ho AS; Cheng CC
    BMC Cancer; 2019 Oct; 19(1):959. PubMed ID: 31619200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
    Koganemaru S; Kuboki Y; Koga Y; Kojima T; Yamauchi M; Maeda N; Kagari T; Hirotani K; Yasunaga M; Matsumura Y; Doi T
    Mol Cancer Ther; 2019 Nov; 18(11):2043-2050. PubMed ID: 31395690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
    Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.